TIRZ / IGF-1 LR3 — 20 mg / 1 mg

TIRZ is shorthand for tirzepatide, a peptide with GIP- and GLP-1-receptor activity. IGF-1 LR3 is an engineered growth-factor analogue with reduced binding-protein interaction, used to support growth responses in cultured cells. The combination name places metabolic-hormone and IGF-receptor pathways together; it does not describe a new endogenous hormone or imply that one ingredient converts into the other.

The SURMOUNT-1 trial reported substantial weight reduction with tirzepatide in adults with obesity or overweight and weight-related complications. The trial did not test LR3 IGF-1 as an accompanying ingredient. Conversely, the growth-factor supplier’s documentation describes laboratory cell-survival and proliferation applications, not a controlled trial of body composition during tirzepatide treatment. A proposed combination rationale may involve maintaining growth signaling while studying weight reduction, but that is an inference from the ingredients. No exact Umbrella blend listing was located in the supplied catalog records. Claims about synergy, muscle retention, or improved metabolic outcomes would therefore require a separate source evaluating this particular combination rather than citation of the individual ingredients alone.